<p>Eton Pharmaceuticals（ETON）正在准备于 2025 年 5 月 13 日发布其季度财报。在公告之前，投资者应注意以下几点。</p>
<p>分析师预计 Eton Pharmaceuticals 的 <strong>每股收益</strong>（EPS）为 0.03 美元。</p>
<p>Eton Pharmaceuticals 的公告备受期待，投资者希望能获得超出预期的消息以及对下个季度的积极指引。</p>
<p>值得新投资者注意的是，指引可能是股价波动的关键因素。</p>
<h3>过去的收益表现</h3>
<p>该公司在上个季度的 EPS 未达到预期，差额为 0.00 美元，导致次日股价上涨 1.36%。</p>
<p>以下是 Eton Pharmaceuticals 的过去表现及其导致的价格变化：</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1747058590_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1747058590_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw"/></p>
<h3>Eton Pharmaceuticals 股票表现</h3>
<p>截至 5 月 9 日，Eton Pharmaceuticals 的股票交易价格为 16.79 美元。在过去 52 周内，股票上涨了 360.74%。鉴于这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
<h3>分析师对 Eton Pharmaceuticals 的看法</h3>
<p>对于投资者而言，了解市场情绪和行业预期至关重要。本分析提供了关于 Eton Pharmaceuticals 的最新见解。</p>
<p>Eton Pharmaceuticals 的共识评级为买入，基于 3 位分析师的评级。平均一年期目标价为 27.67 美元，意味着潜在的 64.8% 上涨空间。</p>
<h3>同业评级分析</h3>
<p>在此比较中，我们探讨了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 这三家行业知名公司的分析师评级和平均一年期目标价，提供了对其相对表现预期和市场定位的见解。</p>
<ul>
<li>分析师目前对 Tilray Brands 持中性态度，平均一年期目标价为 1.0 美元，暗示潜在的 94.04% 下跌空间。</li>
<li>分析师目前对 Zevra Therapeutics 持买入态度，平均一年期目标价为 22.0 美元，暗示潜在的 31.03% 上涨空间。</li>
<li>分析师目前对 EyePoint Pharmaceuticals 持买入态度，平均一年期目标价为 27.33 美元，暗示潜在的 62.78% 上涨空间。</li>
</ul>
<h3>快照：同行分析</h3>
<p>同行分析摘要提供了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 的关键指标的详细审查，提供了对它们在行业内的地位、市场定位和相对表现的有价值见解。</p>
<p>关键要点：</p>
<p>Eton Pharmaceuticals 在同行中在收入增长和毛利润方面排名第一。然而，在股本回报率方面排名最后。</p>
<h3>揭示 Eton Pharmaceuticals 背后的故事</h3>
<p>Eton Pharmaceuticals Inc 是一家总部位于美国的专业制药公司。该公司致力于开发和商业化药品，以满足未满足的患者需求。它拥有四种商业化的罕见疾病产品，分别是用于治疗肾上腺皮质功能不全的 Alkindi Sprinkle；用于治疗高氨血症的 Carglumic Acid；用于治疗同型半胱氨酸尿症的 Betaine Anhydrous；以及用于治疗遗传性酪氨酸血症 1 型（HT-1）的 Nitisinone。该公司还有三种处于后期开发阶段的产品候选者：ET-400、ET-600 和 ZENEO 氢化可的松自动注射器。</p>
<h3>解读 Eton Pharmaceuticals 的财务故事</h3>
<p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相较于同行规模较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
<p><strong>收入增长：</strong> Eton Pharmaceuticals 在过去三个月表现积极。截至 2024 年 12 月 31 日，该公司实现了约 <strong>59.26%</strong> 的稳健收入增长率。这表明公司的顶线收益显著增加。与同行相比，该公司的收入增长落后于行业同行。在医疗保健行业中，其增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> Eton Pharmaceuticals 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率为 <strong>-5.13%</strong>，显示出强大的盈利能力和有效的成本管理。</p>
<p><strong>股本回报率（ROE）：</strong> Eton Pharmaceuticals 的 ROE 超过行业标准，突显了公司的卓越财务表现。其 ROE 为 <strong>-2.96%</strong>，有效利用了股东权益资本。</p>
<p><strong>资产回报率（ROA）：</strong> Eton Pharmaceuticals 的 ROA 超越行业基准，达到 <strong>-1.07%</strong>。这表明其资产管理高效，财务健康状况良好。</p>
<p><strong>债务管理：</strong> Eton Pharmaceuticals 的债务与股本比率低于行业平均水平。其比率为 <strong>1.22</strong>，表明公司对债务融资的依赖较小，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
<p><strong>要查看 Eton Pharmaceuticals 的所有财报发布，请访问我们网站上的财报日历。</strong></p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>

ETON

<p>Eton Pharmaceuticals 将于 2025 年 5 月 13 日公布季度财报，分析师预测每股收益（EPS）为 0.03 美元。该公司过去一年股价上涨了 360.74%，目前交易价格为 16.79 美元。分析师对 Eton 的评级为 “买入”，一年目标价为 27.67 美元，意味着潜在上涨空间为 64.8%。Eton 在同行中在收入增长和毛利润方面排名较高，但在股本回报率方面排名较低。该公司的净利润率为-5.13%，债务与股本比率为 1.22，表明其债务管理有效</p>

<p>Eton Pharmaceuticals ETON is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（ETON）正在准备于 2025 年 5 月 13 日发布其季度财报。在公告之前，投资者应注意以下几点。</p>
</div><p>Analysts expect Eton Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $0.03.</p>
<div class="lb-trans"><p>分析师预计 Eton Pharmaceuticals 的 <strong>每股收益</strong>（EPS）为 0.03 美元。</p>
</div><p>The announcement from Eton Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 的公告备受期待，投资者希望能获得超出预期的消息以及对下个季度的积极指引。</p>
</div><p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<div class="lb-trans"><p>值得新投资者注意的是，指引可能是股价波动的关键因素。</p>
</div><h3>Past Earnings Performance</h3>
<div class="lb-trans"><h3>过去的收益表现</h3>
</div><p>The company's EPS missed by $0.00 in the last quarter, leading to a 1.36% increase in the share price on the following day.</p>
<div class="lb-trans"><p>该公司在上个季度的 EPS 未达到预期，差额为 0.00 美元，导致次日股价上涨 1.36%。</p>
</div><p>Here's a look at Eton Pharmaceuticals's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Eton Pharmaceuticals 的过去表现及其导致的价格变化：</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1747058590_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw" alt="" original-src="https://www.benzinga.com/files/images/story/2025/1747058590_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920"/></p>
<h3>Performance of Eton Pharmaceuticals Shares</h3>
<div class="lb-trans"><h3>Eton Pharmaceuticals 股票表现</h3>
</div><p>Shares of Eton Pharmaceuticals were trading at $16.79 as of May 09. Over the last 52-week period, shares are up 360.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 5 月 9 日，Eton Pharmaceuticals 的股票交易价格为 16.79 美元。在过去 52 周内，股票上涨了 360.74%。鉴于这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
</div><h3>Analysts' Perspectives on Eton Pharmaceuticals</h3>
<div class="lb-trans"><h3>分析师对 Eton Pharmaceuticals 的看法</h3>
</div><p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Eton Pharmaceuticals.</p>
<div class="lb-trans"><p>对于投资者而言，了解市场情绪和行业预期至关重要。本分析提供了关于 Eton Pharmaceuticals 的最新见解。</p>
</div><p>The consensus rating for Eton Pharmaceuticals is Buy, derived from 3 analyst ratings. An average one-year price target of $27.67 implies a potential 64.8% upside.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 的共识评级为买入，基于 3 位分析师的评级。平均一年期目标价为 27.67 美元，意味着潜在的 64.8% 上涨空间。</p>
</div><h3>Analyzing Ratings Among Peers</h3>
<div class="lb-trans"><h3>同业评级分析</h3>
</div><p>In this comparison, we explore the analyst ratings and average 1-year price targets of Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>在此比较中，我们探讨了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 这三家行业知名公司的分析师评级和平均一年期目标价，提供了对其相对表现预期和市场定位的见解。</p>
</div><ul>
<li>Analysts currently favor an Neutral trajectory for Tilray Brands, with an average 1-year price target of $1.0, suggesting a potential 94.04% downside.</li>
<li>Analysts currently favor an Buy trajectory for Zevra Therapeutics, with an average 1-year price target of $22.0, suggesting a potential 31.03% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $27.33, suggesting a potential 62.78% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师目前对 Tilray Brands 持中性态度，平均一年期目标价为 1.0 美元，暗示潜在的 94.04% 下跌空间。</li>
<li>分析师目前对 Zevra Therapeutics 持买入态度，平均一年期目标价为 22.0 美元，暗示潜在的 31.03% 上涨空间。</li>
<li>分析师目前对 EyePoint Pharmaceuticals 持买入态度，平均一年期目标价为 27.33 美元，暗示潜在的 62.78% 上涨空间。</li>
</ul>
</div><h3>Snapshot: Peer Analysis</h3>
<div class="lb-trans"><h3>快照：同行分析</h3>
</div><p>The peer analysis summary offers a detailed examination of key metrics for Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<div class="lb-trans"><p>同行分析摘要提供了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 的关键指标的详细审查，提供了对它们在行业内的地位、市场定位和相对表现的有价值见解。</p>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>关键要点：</p>
</div><p>Eton Pharmaceuticals ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 在同行中在收入增长和毛利润方面排名第一。然而，在股本回报率方面排名最后。</p>
</div><h3>Unveiling the Story Behind Eton Pharmaceuticals</h3>
<div class="lb-trans"><h3>揭示 Eton Pharmaceuticals 背后的故事</h3>
</div><p>Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals Inc 是一家总部位于美国的专业制药公司。该公司致力于开发和商业化药品，以满足未满足的患者需求。它拥有四种商业化的罕见疾病产品，分别是用于治疗肾上腺皮质功能不全的 Alkindi Sprinkle；用于治疗高氨血症的 Carglumic Acid；用于治疗同型半胱氨酸尿症的 Betaine Anhydrous；以及用于治疗遗传性酪氨酸血症 1 型（HT-1）的 Nitisinone。该公司还有三种处于后期开发阶段的产品候选者：ET-400、ET-600 和 ZENEO 氢化可的松自动注射器。</p>
</div><h3>Unraveling the Financial Story of Eton Pharmaceuticals</h3>
<div class="lb-trans"><h3>解读 Eton Pharmaceuticals 的财务故事</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相较于同行规模较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
</div><p><strong>Revenue Growth:</strong> Eton Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>59.26%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Eton Pharmaceuticals 在过去三个月表现积极。截至 2024 年 12 月 31 日，该公司实现了约 <strong>59.26%</strong> 的稳健收入增长率。这表明公司的顶线收益显著增加。与同行相比，该公司的收入增长落后于行业同行。在医疗保健行业中，其增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Eton Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-5.13%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Eton Pharmaceuticals 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率为 <strong>-5.13%</strong>，显示出强大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Eton Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.96%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Eton Pharmaceuticals 的 ROE 超过行业标准，突显了公司的卓越财务表现。其 ROE 为 <strong>-2.96%</strong>，有效利用了股东权益资本。</p>
</div><p><strong>Return on Assets (ROA):</strong> Eton Pharmaceuticals's ROA excels beyond industry benchmarks, reaching <strong>-1.07%</strong>. This signifies efficient management of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Eton Pharmaceuticals 的 ROA 超越行业基准，达到 <strong>-1.07%</strong>。这表明其资产管理高效，财务健康状况良好。</p>
</div><p><strong>Debt Management:</strong> Eton Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <strong>1.22</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Eton Pharmaceuticals 的债务与股本比率低于行业平均水平。其比率为 <strong>1.22</strong>，表明公司对债务融资的依赖较小，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
</div><p><strong>To track all earnings releases for Eton Pharmaceuticals visit their earnings calendar on our site.</strong></p>
<div class="lb-trans"><p><strong>要查看 Eton Pharmaceuticals 的所有财报发布，请访问我们网站上的财报日历。</strong></p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>
</div>

展望：Eton Pharmaceuticals 的盈利预测